The Indian pharmaceuticals market is estimated to have reach $28.8bn in 2018 and is expected to grow at a CAGR of 16.6% in the first half of the forecast period. The market for cardiovascular medication is the fastest growing segment of the Indian pharmaceutical market, followed by the anti-infective segment.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 212-page report you will receive 121 charts– all unavailable elsewhere.
The 212-page report provides clear detailed insight into the Indian Pharmaceutical Market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Indian Pharmaceuticals Market forecasts from 2019-2029
• Revenue forecasts for the leading therapeutic areas in India from 2019-2029:
• Anti-Infectives Therapeutics
• Cardiovascular Therapeutics
• Dermatological Therapeutics
• Diabetes Therapeutics
• Gastrointestinal Therapeutics
• Gynaecology Therapeutics
• CNS Therapeutics
• Pain Relief/Analgesics Therapeutics
• Respiratory Therapeutics
• Vitamins/Minerals/Nutrients Therapeutics
• Other Therapeutics
This report also discusses factors that drive and restrain these submarkets.
• Revenue forecasts for the leading drug types in India from 2019-2029:
• Generic Drugs
• Over-the-Counter (OTC) Drugs
• Patented Drugs
• Biosimilar Drugs
This report also discusses factors that drive and restrain these submarkets.
• Profiles and discusses the leading companies in the Indian pharmaceutical market:
• Abbott Healthcare Private Limited (Abbott India)
• Cadila Healthcare Limited
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd.
• GlaxoSmithKline Pharmaceuticals Limited
• Glenmark Pharmaceuticals Limited
• Intas Pharmaceuticals Limited
• Lupin
• Pfizer Limited
• Sanofi India Limited
• Sun Pharmaceuticals Industries Limited
(Revenues are provided for those companies whose financial information is available on the public domain)
• Analysis of the drivers and restraints of the Indian Pharmaceutical market
• The report also discusses the Porter’s Five Forces Analysis and SWOT Analysis of the Indian Pharmaceuticals Market
• This report also discusses:
• Indian healthcare system and Indian healthcare expenditure
• Indian pharmaceutical regulatory framework, laws & regulations, market access, regulatory bodies
• Disease prevalence and incidence in India, disease mortality rates in India, top causes of death in India, mortality projections from 2019-2029
• What this report provides:
• The Indian pharmaceutical market forecasts and analysis from 2019 to 2029
• Analysis and forecasts for the Indian pharmaceutical submarkets from 2019 to 2029
• Profiles of the leading companies operating within the Indian pharmaceutical industry
• SWOT analysis and Porter’s five forces analysis of the major strengths and weaknesses of the Indian pharmaceutical market together with the opportunities available and the key threats faced
Visiongain’s study is intended for anyone requiring commercial analyses for the Indian Pharmaceuticals Market. You find data, trends and predictions.
Buy our report today Indian Pharmaceutical Market Analysis : Infectious Disease, Cardiovascular, Gastrointestinal, Respiratory, Pain Relief / Analgesics, Diabetes, Vitamins/ Minerals/ Nutrients, Dermatology, CNS, Gynaecology, Generic, OTC, Patented, Biosimilar, Leading Companies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 The Indian Pharmaceutical Market Overview
1.2 Indian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Indian Healthcare: Overview
2.1 India: Demographic Indicators Overview
2.2 Indian Healthcare System: Overview
2.2.1 Rashtriya Swasthya Bima Yojana – Bringing Healthcare Coverage to India’s Poorest Workers
2.3 Analysis of India’s Healthcare Expenditure
3. Indian Pharmaceutical Regulatory Framework
3.1 National Regulatory Bodies
3.1.1 Ministry of Health & Family Welfare (MoHFW)
3.1.2 Ministry of Chemicals and Fertilizers (MoC&F)
3.2 State Regulatory Bodies (State Food and Drug Administrations (FDAs)
3.3 Laws & Regulations for Indian Pharmaceutical Market
3.3.1 The Drugs and Cosmetics Act, 1940
3.3.2 The Pharmacy Act, 1948
3.3.3 The Drugs & Magic Remedies Act, 1954
3.3.4 The Narcotic Drugs and Psychotropic Substances Act, (NDPS)1985
3.3.5 The Medicinal and Toilet Preparations Act, 1956
3.3.6 The Drugs Price Control Order (DPCO), 1995
3.3.7 Indian Patent Act 1970
3.3.8 The Drugs Price Control Order (DPCO), 2013
3.3.9 Good Clinical Practices (GCP)
3.3.10 Good Laboratory Practices (GLP)
3.4 Market Access
3.4.1 Healthcare System
3.4.2 Status of Health Technology Assessment (HTA)
3.4.3 Pricing
3.4.4 Reimbursement of Drugs
4. Indian Pharmaceutical Market: Discussions and Predictions 2019-2029
4.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume
4.2 Indian Pharmaceuticals Market: Overall Revenue Forecast 2018-2029
5. Medical Treatment Needs in India, 2019-2029
5.1 Disease Prevalence in India, 2019-2029
5.2 Disease Incidence in India, 2019-2029
5.3 Disease Mortality Rates in India, 2019-2029
5.3.1 Top Causes of Death in India
5.3.2 Top Causes of Death in India: Mortality Projections, 2019-2029
6. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2019-2029
6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2018
6.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2019-2029
6.3 Infectious Disease Drugs: Overview, 2018
6.3.1 Infectious Disease Drugs Market: Forecast, 2019-2029
6.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2018
6.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death
6.3.4 Tuberculosis Still Rife in India
6.3.5 Malaria, Risk and Opportunity
6.3.6 HIV in India: Growing Therapeutic Area Worth Watching
6.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment
6.4 Cardiovascular Therapeutics Segment: Overview, 2018
6.4.1 Cardiovascular Disease – India’s Leading Cause of Death, 2018
6.4.2 Cardiovascular Drugs Market: Forecast, 2019-2029
6.5 Gastro-Intestinal Therapeutic Segment: Overview, 2018
6.5.1 Gastro-Intestinal Drugs Market: Forecast, 2019-2029
6.5.2 Gastro-Intestinal Therapeutics in India: Challenges and Opportunities
6.5.3 Drivers and Restraints for the Gastro-Intestinal Therapeutics Segment
6.6 Respiratory Therapeutic Segment: Overview, 2018
6.6.1 Respiratory Disease Drugs Market: Forecast, 2019-2029
6.6.2 Drivers and Restraints for the Respiratory Therapeutics Segment
6.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2018
6.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2019-2029
6.7.2 Drivers and Restraints for the Pain Relief/Analgesics Therapeutics Segment
6.8 Diabetes Therapeutic Segment: Overview, 2018
6.8.1 Diabetes Therapeutics Market: Forecast, 2019-2029
6.8.2 Drivers and Restraints for the Diabetes Therapeutics Segment
6.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2018
6.9.1 Vitamins / Minerals / Nutrients Therapeutics Market: Forecast, 2019-2029
6.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
6.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Therapeutics Segment
6.10 Dermatological Therapeutic Segment: Overview, 2018
6.10.1 Dermatological Therapeutics Market: Forecast, 2019-2029
6.10.2 Drivers and Restraints for the Dermatological Therapeutics Segment
6.11 Central Nervous System (CNS) Therapeutics: Overview, 2018
6.11.1 CNS Drugs Market: Forecast, 2019-2029
6.11.2 Intentional Injury Among the Top 10 Leading Causes of Death, 2018
6.11.3 India’s Aging Population: Driver for the CNS Segment
6.11.4 Drivers and Restraints for the CNS Therapeutics Segment
6.12 Gynaecological Treatment Market Overview: 2018
6.12.1 Infant Mortality Still High in India
6.12.2 Indian Gynaecological Treatments Market: Forecast, 2019-2029
6.12.3 Drivers and Restraints for the Gynaecological Segment
6.13 Other Pharmaceutical Products Market Overview: 2018
6.13.1 Incidence of Cancer is Rising in India
6.13.2 Indian Other Treatments Market: Forecast, 2019-2029
7. Indian Pharmaceutical Market: Leading Drug Types, 2019-2029
7.1 Drug Types in the Indian Market: Overview, 2018
7.2 Growth Forecasts for Leading Drug Types in India, 2019-2029
7.3 Generic Drugs Dominate the Indian Pharmaceutical Market
7.3.1 Indian Generics: Overview, 2018
7.3.2 Indian Generic Drugs Market: Forecast, 2018-2029
7.3.3 Branded Generics Preferred by Many Indian Patients
7.3.4 Drivers and Restraints for the Generic Drug Market in India
7.4 Indian Over-The-Counter (OTC) Drugs Market: Overview, 2018
7.4.1 Indian OTC Market: Forecast, 2019-2029
7.4.2 Drivers and Restraints of the Indian OTC Market
7.5 Indian Patented Drugs Market: Overview, 2018
7.5.1 Indian Patented Drugs Market: Forecasts, 2019-2029
7.5.2 Drivers and Restraints for the Indian Patented Drugs Market
7.6 Indian Biosimilar Drugs, 2018
7.6.1 Indian Biosimilar Drugs Market: Forecast, 2019-2029
7.6.2 A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
7.6.3 Drivers and Restraints of the Indian Biosimilar Drugs Market
8. The Leading Companies in the Indian Pharmaceuticals Market
8.1 Indian Pharmaceuticals Market Overview
8.1.1 Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
8.2 Top 50 Domestic Indian Pharmaceutical Companies, 2018
8.3 Sun Pharmaceuticals Industries Limited
8.3.1 Sun Pharma: Global Presence
8.3.1.1 Sun Pharmaceutical Sales by Region, 2017
8.3.2 Sun Pharmaceuticals Business Performance 2008-2017
8.3.3 Sun Pharmaceutical: The Acquisition of Ranbaxy Laboratories is the Largest Ever Deal Made by an Indian Pharmaceutical Company
8.3.3.1 Other Major M&A Activity
8.4 Abbott Healthcare Private Limited (Abbott India)
8.4.1 Abbott India: Business Performance 2007-2017
8.4.2 Abbott India: Major and Recent M&A Activity
8.5 Cipla Ltd.
8.5.1 Cipla: Business Performance 2008-2017
8.5.2 Cipla Ltd.: Major and Recent Activity
8.6 Cadila Healthcare Limited
8.6.1 Cadila: Business Performance 2008-2017
8.6.2 Cadila Healthcare Revenue by Therapeutic Area 2017
8.7 GlaxoSmithKline Pharmaceuticals Limited
8.7.1 GlaxoSmithKline India: Business Performance 2008-2017
8.8 Pfizer Limited., India
8.8.1 Pfizer India: Business Performance 2008-2017
8.9 Lupin
8.9.1 Lupin: Business Performance 2008-2017
8.9.2 Lupin Revenue by Therapeutic Area, 2017
8.10 Sanofi India Limited
8.10.1 Sanofi India Limited: Business Performance 2008-2017
8.10.2 Sanofi India Limited Revenue by Business Segments, 2017
8.10.3 Sanofi India Limited Revenue by Geographical Area, 2017
8.10.4 Sanofi India Limited Recent Activities
8.11 Intas Pharmaceuticals Limited
8.11.1 Intas Pharmaceuticals Limited: Business Performance 2008-2017
8.12 Dr. Reddy’s Laboratories Ltd.
8.12.1 Dr. Reddy’s Laboratories Ltd: Business Performance 2008-2017
8.12.2 Dr. Reddy’s Laboratories Ltd. Revenue by Business Segments, 2017
8.12.3 Dr. Reddy’s Laboratories Ltd Global Generics Segment Revenue by Geographical Area, 2017
8.13 Glenmark Pharmaceuticals Limited
8.13.1 Glenmark Pharmaceuticals Limited: Business Performance 2008-2017
8.13.2 Glenmark Pharmaceuticals Limited Revenue by Geographical Area, 2017
8.13.3 Glenmark Pharmaceuticals Limited Recent Activities
9. Qualitative Analysis of the Indian Pharmaceuticals Market, 2018
9.1 Indian Pharmaceutical Market: Drivers and Restraints
9.2 SWOT Analysis of the Indian Pharmaceuticals Market
9.3 Strengths
9.3.1 Increasing Investment in the Healthcare System
9.3.2 The Disease Burden and GDP Growing
9.3.3 India’s Population Set to Become the World’s Largest by 2030
9.3.4 India Popular for Pharmaceutical Outsourcing
9.4 Weaknesses
9.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceuticals Market
9.4.2 Poor Infrastructure Threatens to Hinder Market Potential
9.4.3 Intense Competition Driving Down Drug Prices
9.5 Opportunities
9.5.1 Global Demand for Generics Rising
9.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas
9.5.3 Significant Investment from MNCs Expected
9.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
9.6 Threats
9.6.1 Rise of Other Low-Cost Generic Exporters
9.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure?
9.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
9.7 Porter’s Five Forces Analysis of the Indian Pharmaceuticals Market
9.7.1 Rivalry Among Competitors [High]
9.7.2 Threat of New Entrants [Low]
9.7.3 Power of Suppliers [Medium]
9.7.4 Power of Buyers [High]
9.7.5 Threat of Substitutes [Low]
10. Conclusion
10.1 The Indian Pharmaceuticals Market: Growing Global Market Share
10.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
10.3 Commercial Drivers of the Indian Pharmaceuticals Market
10.4 Commercial Restraints of the Indian Pharmaceuticals Market
10.5 Concluding Remarks
11. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 4.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
Table 5.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
Table 5.3 Causes of Death in India by World Ranking, 2014
Table 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2018, 2024, 2029
Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2018-2029
Table 6.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.5 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.6 The Indian Respiratory Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.7 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.8 Indian Diabetes Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.9 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.10 Indian Dermatological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.11 Indian CNS Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.12 Indian Gynaecological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.13 Indian Other Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2019, 2024 and 2029
Table 7.2 Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2019-2029
Table 7.3 Indian Generic Drugs Market: Revenue ($bn), AGR (%) and CAGR (%) 2018-2029
Table 7.4 Indian OTC Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 7.5 Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 7.6 Selected Biosimilar Therapeutics on the Indian Market, 2018
Table 7.7 Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 7.8 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
Table 7.9 Selected Late-Stage Biosimilar Pipeline Products, 2015
Table 8.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs. m), Revenue ($m) and Market Share (%), 2017
Table 8.2 Sun Pharmaceuticals: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Business Area, FY 2017
Table 8.3 Sun Pharmaceuticals: Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.4 Sun Pharmaceuticals: M&A Activity, 1997-2016
Table 8.5 Abbott India: Market Share (%) and Market Rank of Key Brands
Table 8.6 Abbott India: Revenue (Rs. m), AGR (%) and CAGR (%), 2006-2017
Table 8.7 Cipla: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.8 Cipla: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2017
Table 8.9 Cadila Healthcare Ltd.: Total Revenue (Rs. m), Total Revenue ($m), AGR (%) and CAGR (%), 2008-2017
Table 8.10 Cadila Healthcare Ltd.: Revenue (Rs.m) and Revenue Share (%) by Therapeutic Area, 2017
Table 8.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017
Table 8.12 GlaxoSmithKline India Total Revenue (Rs. m), AGR (%) and CAGR (%), 2007-2017
Table 8.13 Pfizer India: Leading Brands on the Indian Market 2017
Table 8.14 Pfizer India: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
Table 8.15 Lupin: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.16 Lupin: Revenue Share (%) by Therapeutic Area, 2017
Table 8.17 Sanofi India Limited: Major Products,2017
Table 8.18 Sanofi India Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.19 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Domestic Segment, 2017
Table 8.20 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Branded drugs, 2017
Table 8.21 Sanofi India Limited: Revenue (Rs. m), and Revenue Share (%) by Geographical Area, 2017
Table 8.22 Intas Pharmaceuticals Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.23 Dr. Reddy’s Laboratories Ltd: Major Products,2017
Table 8.24 Dr. Reddy’s Laboratories Ltd: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.25 Dr. Reddy’s Laboratories Ltd: Revenue (Rs. m), and Revenue Share (%) by Business Segment, 2017
Table 8.26 Dr. Reddy’s Laboratories Ltd: Revenue (Rs.m), and Revenue Share (%) by Geographical Area, 2017
Table 8.27 Glenmark Pharmaceuticals Limited: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
Table 9.1 SWOT Analysis of the Indian Pharmaceuticals Market
List of Figures
Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
Figure 2.1 Indian Population: Rural and Urban (Mn),1960-2020
Figure 2.2 Indian Population: Total (Mn) and Annual Population Growth Rate (%), 1960-2020
Figure 2.3 Indian GDP ($bn) and Growth Rate (%), 2010-2020
Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2008-2020
Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2014
Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2008-2014
Figure 3.1 National Regulatory Bodies Regulating the Indian Pharmaceutical Market
Figure 4.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
Figure 6.1 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2018
Figure 6.2 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2024
Figure 6.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2029
Figure 6.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
Figure 6.6 Infectious Diseases Therapeutics Market in India: Drivers and Restraints, 2018-2029
Figure 6.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.8 Cardiovascular Diseases Therapeutics Market in India: Drivers and Restraints
Figure 6.9 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.10 Gastro-intestinal Therapeutics Market in India: Drivers and Restraints
Figure 6.11 Indian Respiratory Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.12 Respiratory Therapeutics Market in India: Drivers and Restraints, 2018-2029
Figure 6.13 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.14 Pain Relief/Analgesics Therapeutics Market in India: Drivers and Restraints, 2018-2029
Figure 6.15 Indian Diabetes Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.16 Diabetes Therapeutics Market in India: Drivers and Restraints
Figure 6.17 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.18 Vitamins / Minerals / Nutrients Therapeutics Market in India: Drivers and Restraints
Figure 6.19 Indian Dermatological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.20 Dermatological Therapeutics Market in India: Drivers and Restraints
Figure 6.21 Indian CNS Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.22 CNS Therapeutics Market in India: Drivers and Restraints
Figure 6.23 Indian Gynaecological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.24 Gynaecological Therapeutics Market in India: Drivers and Restraints
Figure 6.25 Indian Other Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2019
Figure 7.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2024
Figure 7.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2029
Figure 7.4 Indian Generic Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.5 Generic Drugs Market in India: Drivers and Restraints
Figure 7.6 Indian OTC Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.7 OTC Drugs Market in India: Drivers and Restraints
Figure 7.8 Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.9 Patented Drugs Market in India: Drivers and Restraints
Figure 7.10 Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.11 Biosimilar Drug Market in India: Drivers and Restraints
Figure 8.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, FY 2017
Figure 8.2 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2008-2017
Figure 8.3 Abbott India: Revenue (Rs. m) and AGR (%), 2006-2017
Figure 8.4 Cipla Revenue (Rs.m) and AGR (%), 2008-2017
Figure 8.5 Cadila Healthcare Ltd.: Revenue Share (%), by Business Area, 2017
Figure 8.6 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2007-2017
Figure 8.7 Pfizer India: Revenue (Rs.m) and AGR (%), 2007-2016
Figure 8.8 Lupin: Revenue (Rs.m) and AGR (%), 2008-2017
Figure 8.9 Lupin: Revenue Share (%) by Therapeutic Area, 2017
Figure 8.10 Sanofi India Limited: Revenue ($m) and AGR (%), 2008-2017
Figure 8.11 Sanofi India Limited: Revenue Distribution by Business Segments, 2017
Figure 8.12 Sanofi India Limited: Revenue Distribution by Domestic Segments, 2017
Figure 8.13 Sanofi India Limited: Revenue Distribution by Geographical Area, 2017
Figure 8.14 Intas Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2008-2017
Figure 8.15 Dr. Reddy’s Laboratories Ltd: Revenue ($m) and AGR (%), 2008-2017
Figure 8.16 Dr. Reddy’s Laboratories Ltd: Revenue Distribution by Business Segments, 2017
Figure 8.17 Dr. Reddy’s Laboratories Ltd: Global Generics Segment Revenue Distribution by Geographical Area, 2017
Figure 8.18 Glenmark Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2007-2017
Figure 8.19 Glenmark Pharmaceuticals Limited: Revenue Distribution by Geographical Area, 2017
Figure 9.1 Indian Pharmaceuticals Market: Drivers and Restraints
Figure 9.2 Porter’s Five Forces Analysis of the Indian Pharmaceuticals Market
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
